Patients using the weight-loss medication Mounjaro have reported difficulties in obtaining the drug, raising concerns about their health amid increased demand. This surge in interest follows Eli Lilly’s announcement of a significant price increase effective September 1, 2023, where costs could rise by up to 170%. This price hike means a month’s supply of the highest dosage will increase from £122 to £330.
Eli Lilly has advised against stockpiling and has requested UK distributors to cease orders from pharmacies to manage supply. Pharmacies have indicated they are prioritizing existing patients over new users and expect normal supply levels to resume by early September. The National Pharmacy Association (NPA) has noted a notable spike in demand, particularly in light of the upcoming price adjustments.
Individual cases highlight the challenges faced by patients. For instance, Lynne Massey-Davis, who has benefitted from the drug for weight management, is currently experiencing delivery issues and has been placed in a waiting queue. She is concerned about the potential impact on her health and plans to share doses with a friend until her own supply arrives.
Experts urge against bulk ordering to prevent exacerbating shortages and caution against purchasing from unlicensed sellers due to safety concerns. Advice includes consulting local pharmacies for options and maintaining healthy lifestyle habits. Alternative medications like Wegovy should be used only under medical supervision, according to some pharmacy professionals.
Several patients, including those prescribed Mounjaro for type 2 diabetes, are also facing supply shortages. Eli Lilly has stated that pharmacies should have allocations for stock orders and emphasized adherence to treatment plans to reduce local disruptions. The situation remains fluid as the company works to replenish supplies following the impending price changes.
Source: https://www.bbc.com/news/articles/clyr8ynx41yo?at_medium=RSS&at_campaign=rss